SB465
In Senate Committeeclassifying xylazine as a schedule III controlled drug.
Senate
Judiciary
2026 Session
Status
Introduced
Senate Committee
Senate Vote
House
House Vote
Governor
Hearing
No upcoming hearing scheduled.
Testimony
Support
15
Oppose
3
18 total submissions
Bill Text
Loading bill text...